Title:
NOVEL INDIRUBIN DERIVATIVE HAVING HETEROBICYCLIC RESIDUE AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/153630
Kind Code:
A1
Abstract:
The present invention relates to a novel indirubin derivative having a heterobicyclic residue, and the use thereof as fms-like tyrosine kinase 3 (FLT3) and rearranged during transfection (RET) kinase inhibitors. A compound of the present invention effectively inhibits FLT3 and RET kinase activities and thus may be utilized for preventing or treating mutant FLT3- and mutant RET-related diseases, particularly acute myeloid leukemia (AML).
More Like This:
| JP2023536920 | salt-inducible kinase inhibitor |
| WO/2019/204505 | K-RAS MODULATORS WITH A VINYL SULFONAMIDE MOIETY |
| WO/2009/114575 | TRICYCLIC SPIRO PYRIMIDINE DERIVATIVES AS HISTAMINE H4 LIGAND |
Inventors:
JANG SOO YEON (KR)
KIM MYUNG JIN (KR)
PARK JIN HEE (KR)
LEE SO DEOK (KR)
OH SU JIN (KR)
LEE EUN JI (KR)
KIM YONG CHUL (KR)
KIM WOO CHAN (KR)
LEE JE HEON (KR)
KIM MYUNG JIN (KR)
PARK JIN HEE (KR)
LEE SO DEOK (KR)
OH SU JIN (KR)
LEE EUN JI (KR)
KIM YONG CHUL (KR)
KIM WOO CHAN (KR)
LEE JE HEON (KR)
Application Number:
PCT/KR2022/021194
Publication Date:
August 17, 2023
Filing Date:
December 23, 2022
Export Citation:
Assignee:
PELEMED CO LTD (KR)
International Classes:
C07D487/10; A61K31/404; A61K31/4995; A61P35/02; C07D403/14; C07D487/08
Domestic Patent References:
| WO2014153023A1 | 2014-09-25 | |||
| WO2007099402A2 | 2007-09-07 |
Foreign References:
| KR20210071858A | 2021-06-16 |
Other References:
GABORIAUD-KOLAR NICOLAS, MYRIANTHOPOULOS VASILLIOS, VOUGOGIANNOPOULOU KONSTANTINA, GEROLYMATOS PANAGIOTIS, HORNE DAVID A., JOVE RI: "Natural-Based Indirubins Display Potent Cytotoxicity toward Wild-Type and T315I-Resistant Leukemia Cell Lines", JOURNAL OF NATURAL PRODUCTS, AMERICAN CHEMICAL SOCIETY, US, vol. 79, no. 10, 28 October 2016 (2016-10-28), US , pages 2464 - 2471, XP055811640, ISSN: 0163-3864, DOI: 10.1021/acs.jnatprod.6b00285
JEONG PYEONGHWA; MOON YEONGYU; LEE JE-HEON; LEE SO-DEOK; PARK JIYEON; LEE JUNGEUN; KIM JIHEON; LEE HYO JEONG; KIM NA YOON; CHOI JU: "Discovery of orally active indirubin-3′-oxime derivatives as potent type 1 FLT3 inhibitors for acute myeloid leukemia", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, ELSEVIER, AMSTERDAM, NL, vol. 195, 6 March 2020 (2020-03-06), AMSTERDAM, NL , XP086144024, ISSN: 0223-5234, DOI: 10.1016/j.ejmech.2020.112205
BROWN P ET AL., EUROPEAN JOURNAL OF CANCER, 2004, pages 707 - 721
CAROW ET AL., BLOOD, vol. 87, no. 3, 2 February 1996 (1996-02-02)
BRIG ET AL., BLOOD, vol. 80, no. 10, November 1992 (1992-11-01)
ABU-DUHIER ET AL., BRITISH JOURNAL OF HAEMATOLOGY, vol. 111, no. 1, October 2000 (2000-10-01), pages 190 - 5
YAMAMOTO ET AL., BLOOD, vol. 97, no. 8, 15 April 2001 (2001-04-15)
GER ET AL., ANTICANCER RESEARCH, vol. 38, 2018, pages 5759 - 5765
ZHU ET AL., FRONTIERS IN PHARMACOLOGY, vol. 12, May 2021 (2021-05-01)
MULLIGAN, L. M., NATURE REVIEWS CANCER, vol. 14, 2014, pages 173 - 186
KOHNO, T. ET AL., NATURE MEDICINE, vol. 18, no. 3, 2012, pages 375 - 377
MATSUBARA, D. ET AL., JOURNAL OF THORACIC ONCOLOGY, vol. 7, no. 12, 2012, pages 1872 - 1876
RUDAT ET AL., LEUKEMIA, vol. 32, 2018, pages 2189 - 2202
JEONG PYEONGHWA; MOON YEONGYU; LEE JE-HEON; LEE SO-DEOK; PARK JIYEON; LEE JUNGEUN; KIM JIHEON; LEE HYO JEONG; KIM NA YOON; CHOI JU: "Discovery of orally active indirubin-3′-oxime derivatives as potent type 1 FLT3 inhibitors for acute myeloid leukemia", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, ELSEVIER, AMSTERDAM, NL, vol. 195, 6 March 2020 (2020-03-06), AMSTERDAM, NL , XP086144024, ISSN: 0223-5234, DOI: 10.1016/j.ejmech.2020.112205
BROWN P ET AL., EUROPEAN JOURNAL OF CANCER, 2004, pages 707 - 721
CAROW ET AL., BLOOD, vol. 87, no. 3, 2 February 1996 (1996-02-02)
BRIG ET AL., BLOOD, vol. 80, no. 10, November 1992 (1992-11-01)
ABU-DUHIER ET AL., BRITISH JOURNAL OF HAEMATOLOGY, vol. 111, no. 1, October 2000 (2000-10-01), pages 190 - 5
YAMAMOTO ET AL., BLOOD, vol. 97, no. 8, 15 April 2001 (2001-04-15)
GER ET AL., ANTICANCER RESEARCH, vol. 38, 2018, pages 5759 - 5765
ZHU ET AL., FRONTIERS IN PHARMACOLOGY, vol. 12, May 2021 (2021-05-01)
MULLIGAN, L. M., NATURE REVIEWS CANCER, vol. 14, 2014, pages 173 - 186
KOHNO, T. ET AL., NATURE MEDICINE, vol. 18, no. 3, 2012, pages 375 - 377
MATSUBARA, D. ET AL., JOURNAL OF THORACIC ONCOLOGY, vol. 7, no. 12, 2012, pages 1872 - 1876
RUDAT ET AL., LEUKEMIA, vol. 32, 2018, pages 2189 - 2202
Attorney, Agent or Firm:
GURU IP LAW FIRM (KR)
Download PDF: